Why Is Novartis Stock Trading Lower - Novartis (NYSE:NVS)

Pharmalittle: We're reading about a memo on RFK Jr., a Novartis blockbuster's failed trial, and more

In what appears to be a first, the FDA issued a report showing potential signals of serious risks caused by drugs in the first quarter of 2025

Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study

Why Is Novartis Stock Trading Lower - Novartis (NYSE:NVS)

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial data.

Novartis fails in late-stage trial for Cosentyx in giant cell arteritis

Novartis drug flunks phase 3 test in giant cell arteritis

Novartis hopes of bringing Cosentyx to patients with giant cell arteritis seem to be over after the drug missed all the endpoints in a phase 3 trial.

Novartis Cosentyx fails in late-stage giant cell arteritis trial